| 4.18 0.38 (10%) | 05-22 16:00 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 5.29 |
1-year : | 6.17 |
| Resists | First : | 4.53 |
Second : | 5.29 |
| Pivot price | 4.01  |
|||
| Supports | First : | 3.97 |
Second : | 3.64 |
| MAs | MA(5) : | 3.85 |
MA(20) : | 4.09 |
| MA(100) : | 4.36 |
MA(250) : | 4.05 |
|
| MACD | MACD : | -0.2 |
Signal : | -0.2 |
| %K %D | K(14,3) : | 33.2 |
D(3) : | 19.3 |
| RSI | RSI(14): 53.7 |
|||
| 52-week | High : | 5.36 | Low : | 3.41 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ MOLN ] has closed below upper band by 30.3%. Bollinger Bands are 22.3% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 4.35 - 4.37 | 4.37 - 4.39 |
| Low: | 3.96 - 3.98 | 3.98 - 3.99 |
| Close: | 4.15 - 4.18 | 4.18 - 4.21 |
Molecular Partners AG operates as a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic proteins. Its products candidates include Abicipar, a DARPin therapeutic candidate, which is in Phase III clinical trials for the treatment of neovascular wet age-related macular degeneration, as well as for diabetic macular edema; and MP0420, a multi-specific DARPin therapeutic candidate for the SARS-CoV-2 virus. The company develops MP0310, which is in Phase Ia clinical trials for immuno-oncology; MP0317, a tumor-localized immune agonist that activates immune cells in the tumor, which is in Phase I clinical trials; and MP0274 that is in Phase I clinical trials for HER2-positive cancers. It also develops MP0423 for treating COVID-19; MP0533, a CD3 T cell candidate for acute myeloid leukemia; and MP0250 for vascular endothelial growth factor, hepatocyte growth factor, and human serum albumin to increase half-life. Molecular Partners AG has agreements and collaboration with Novartis AG to develop, manufacture, and commercialize DARPin-conjugated radioligand therapies; Amgen SA; Allergan, Inc.; and discovery alliance with AbbVie Inc. in ophthalmology, as well as other third-party collaborators. The company was incorporated in 2004 and is headquartered in Schlieren, Switzerland.
Wed, 13 May 2026
Molecular Partners AG Stock 12‑Month Price Target Raised to $10.31, Implies 155% Upside - TradingView
Tue, 12 May 2026
Radio-DARPin therapy MP0712 enters US trial, first results expected 2026 - Stock Titan
Tue, 12 May 2026
Molecular Partners (NASDAQ: MOLN) details Q1 2026 loss and cash runway - Stock Titan
Mon, 04 May 2026
Molecular Partners AG to Present Lead Radio-DARPin Candidate MP0712 at Upcoming Scientific Conferences - Quiver Quantitative
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Outperform |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Neutral |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 38 (M) |
| Shares Float | 20 (M) |
| Held by Insiders | 0 (%) |
| Held by Institutions | 9.6 (%) |
| Shares Short | 10 (K) |
| Shares Short P.Month | 16 (K) |
| EPS | -1.99 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 2.75 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -28.9 % |
| Return on Equity (ttm) | -59.1 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | -1.05 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.39 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -48 (M) |
| Levered Free Cash Flow | -25 (M) |
| PE Ratio | -2.12 |
| PEG Ratio | 0 |
| Price to Book value | 1.51 |
| Price to Sales | 0 |
| Price to Cash Flow | -3.24 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|